Miravant Medical Technologies Inc. (MRVT)
Miravant Medical Technologies Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Santa Barbara, CA, US. The stock last traded at $0.00, up 29900.00% on the session, giving a market capitalisation of $113,571. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of -7.25 implies it has historically moved less than the broad market.
Miravant Medical Technologies Inc. operates as a specialized firm dedicated to pharmaceutical research and development. A cornerstone of its work involves PhotoPoint, an innovative photodynamic therapy designed to eradicate cancerous cells when exposed to light. Furthermore, the company manufactures the essential light-generating and light-delivery devices required for this treatment. Miravant's product pipeline includes several therapeutic agents: PHOTREX, which is aimed at treating wet age-related macular degeneration (AMD); MV9411, a photoreactive compound developed for managing plaque psoriasis; MV0633, which targets conditions like atherosclerosis, vulnerable atherosclerotic plaque, and restenosis; MV2101, designed to address vascular access graft disease in hemodialysis patients; and MV6401, a treatment under development for solid tumors. The organization, originally established as PDT, Inc., officially adopted its current name, Miravant Medical Technologies Inc., in September of 1997. Founded in 1989, it maintains its corporate headquarters in Santa Barbara, California.
Miravant Medical Technologies Inc. is most often compared with the following Healthcare names: